CompanyHealthEnterprise
BlueSphere Bio
BlueSphere Bio is a Pittsburgh-based clinical-stage biotechnology company developing personalized T-cell receptor (TCR) therapies for cancer. Spun out of the University of Pittsburgh and UPMC Enterprises in 2017, the company's proprietary TCXpress platform rapidly discovers and screens natural T-cell receptors that can target cancer antigens hidden inside cells - a reach beyond what conventional CAR-T therapies achieve. Its lead programs target high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.
2017Founded
PittsburghHQ
$45.6 million (initial tranche; up to $105M targeted)Series B
tcr therapyt-cell therapyimmunotherapyoncologycancerbiotech